U.S. patent number 7,611,856 [Application Number 10/980,346] was granted by the patent office on 2009-11-03 for mass spectrometry-based methods for detection and differentiation of botulinum neurotoxins.
This patent grant is currently assigned to Los Alamos National Security, LLC. Invention is credited to John R. Barr, Anne E. Boyer, Suzanne R. Kalb, Hercules Moura, Jurgen G. Schmidt, Adrian R. Woolfitt.
United States Patent |
7,611,856 |
Schmidt , et al. |
November 3, 2009 |
Mass spectrometry-based methods for detection and differentiation
of botulinum neurotoxins
Abstract
The present invention is directed to a method for detecting the
presence of clostridial neurotoxins in a sample by mixing a sample
with a peptide that can serve as a substrate for proteolytic
activity of a clostridial neurotoxin; and measuring for proteolytic
activity of a clostridial neurotoxin by a mass spectroscopy
technique. In one embodiment, the peptide can have an affinity tag
attached at two or more sites.
Inventors: |
Schmidt; Jurgen G. (Los Alamos,
NM), Boyer; Anne E. (Atlanta, GA), Kalb; Suzanne R.
(Atlanta, GA), Moura; Hercules (Tucker, GA), Barr; John
R. (Suwannee, GA), Woolfitt; Adrian R. (Atlanta,
GA) |
Assignee: |
Los Alamos National Security,
LLC (Los Alamos, NM)
|
Family
ID: |
35732766 |
Appl.
No.: |
10/980,346 |
Filed: |
November 3, 2004 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20060024763 A1 |
Feb 2, 2006 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
60517792 |
Nov 5, 2003 |
|
|
|
|
Current U.S.
Class: |
435/7.72 |
Current CPC
Class: |
G01N
33/6848 (20130101); C12Q 1/37 (20130101) |
Current International
Class: |
G01N
30/72 (20060101) |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
WO03001206 |
|
Jan 2003 |
|
WO |
|
WO 03001206 |
|
Jan 2003 |
|
WO |
|
Other References
Kalb et al. (Anal. Biochem., 351:84-92, 2006). cited by examiner
.
Boyer et al. (Anal. Chem., 77:3916-3924, 2005). cited by examiner
.
Schmidt et al., Anal. Biochem., 296:130-137, 2001. cited by
examiner .
Schmidt and Stafford (Appl. Environ. Microbiol., 69:297-303, 2003).
cited by examiner .
Hortin et al. (Clin. Chem., 47:215-222, 2001). cited by examiner
.
Bowers et al. (Anal. Chem., 65:475R-479R, 1993). cited by examiner
.
Schmidt et al., Appl. Microbiol., v69 (1) pp. 297-303 (2003). cited
by other.
|
Primary Examiner: Mondesi; Robert B
Assistant Examiner: Gangle; Brian J
Attorney, Agent or Firm: Cottrell; Bruce H. Jones; Juliet
A.
Government Interests
STATEMENT REGARDING FEDERAL RIGHTS
This invention was made with government support under Contract No.
W-7405-ENG-36 awarded by the U.S. Department of Energy. The
government has certain rights in the invention.
Parent Case Text
RELATED APPLICATIONS
This application claims the benefit of the filing of U.S.
provisional application 60/517,792 filed Nov. 5, 2003.
Claims
What is claimed is:
1. A method for detecting the presence of clostridial botulinum
neurotoxins in a sample comprising the steps of: a) mixing a sample
that may comprise serotypes of clostridial neurotoxins with a
peptide substrate, wherein said peptide substrate is
KGSNRTRIDEANORATRMLGGK-(SEQ ID NO: 1), and optionally, one or more
peptide substrates selected from the group consisting of SEQ ID
NO:14, 21, and 28, for proteolytic activity of said clostridial
neurotoxin serotypes, such that at least a portion of the amount of
the substrate is proteolytically cleaved by a serotype to produce a
mixture comprising uncleaved substrate and peptide cleavage
products; b) analyzing the mixture on a mass spectrometer to
produce a signal corresponding to the mass of at least one peptide
cleavage product; c) using the signal corresponding to the peptide
cleavage products to identify the clostridial neurotoxin serotype;
d) quantitating the amount of proteolytic cleavage of the peptide
substrate for the clostridial neurotoxin serotype by stable isotope
dilution mass spectrometry.
2. The method of claim 1 wherein said peptide substrate has an
affinity tag attached at two or more sites.
3. The method of claim 1 wherein said botulinum neurotoxin is
selected from the group consisting of serotype A, serotype B,
serotype C, serotype D, serotype E, serotype F, serotype G, and
mixtures thereof.
4. The method of claim 1 wherein said botulinum neurotoxin is of
serotype A.
5. The method of claim 1 wherein said botulinum neurotoxin is of
serotype B.
6. The method of claim 1 wherein said botulinum neurotoxin is of
serotype E.
7. The method of claim 1 wherein said botulinum neurotoxin is of
serotype F.
8. The method of claim 2 wherein said affinity tag is biotin.
9. The method of claim 2 wherein said affinity tag is a fluorous
compound.
10. The method of claim 2, further comprising the step of recovery
of uncleaved substrate and peptide cleavage products via said
affinity tags.
11. The method of claim 1, wherein the sample is a biological
sample comprising food, serum, stool, or combinations thereof.
12. The method of claim 1 wherein said botulinum neurotoxin
comprises a mixture of at least two serotypes selected from the
group consisting of serotype A, serotype B, serotype C, serotype D,
serotype E, serotype F, serotype G, and mixtures thereof.
13. The method of claim 1 wherein said botulinum neurotoxin
comprises a mixture of at least three serotypes selected from the
group consisting of serotype A, serotype B, serotype C, serotype D,
serotype E, serotype F, serotype G, and mixtures thereof.
Description
FIELD OF THE INVENTION
The present invention relates to detection methods for botulinum
neurotoxins and to mass spectrometry-based methods for detection
and differentiation of botulinum neurotoxins.
BACKGROUND OF THE INVENTION
The neurotoxins produced by Clostridium botulinum (Botulinum
Neurotoxins, BoNT) are among the most poisonous substances known.
There are seven distinct serotypes of BoNTs (A-G), four of which
are generally found to cause botulism in humans (A, B, E and F).
There are several challenges in the diagnosis and treatment of
botulism. Since the toxicity of BoNT is so great, it is necessary
that BoNT can be detected at very low concentrations, preferably as
the active toxin. The identification of the serotype is important
for the most effective treatment. It is also imperative that the
diagnosis be made rapidly since the equine-based treatment can have
several substantial side effects.
The current standard for detecting botulinum toxins in, e.g., food,
is the mouse lethality bioassay. Not only does this process require
the use of animals, but also the process takes nearly a week to
complete.
The current methods for detecting BoNT include a mouse bioassay and
an enzyme-linked immunosorbent assay (ELISA). The mouse bioassay is
currently the gold standard and is the only widely accepted method
for the detection of BoNT. Mixtures of neutralizing antibodies are
given to mice in conjunction with the sample in question to
differentiate the toxin serotype. Mice receiving the appropriate
anti-BoNT serotype antibody along with the toxic sample do not show
symptoms and survive, while mice treated with the other serotype
antibodies show symptoms and die. Importantly, this assay measures
only active toxin. The mouse bioassay is very sensitive, detecting
as little as 10 picograms (pg) of active toxin which is defined as
1 mouse LD.sub.50 or 1 unit of BoNT. However, the mouse bioassay
can be slow (taking up to 4 days) for final results and it requires
the sacrifice of many animals. It is highly desirable to have a
more rapid technique of detecting botulinum toxins.
The ELISA is much more rapid, but is less sensitive, is problematic
in certain matrices, shows cross reactivity between BoNT serotypes,
and measures inactive toxin along with active toxin. The ELISA is
currently used primarily as a fast screening technique and results
are verified by the mouse bioassay.
Among recent approaches are: (1) U.S. Pat. No. 5,965,699 by Schmidt
et al. wherein an assay for the proteolytic activity of type A
botulinum toxin is described involving addition of a fluorigenic
reagent that reacts with one of the proteolytic products to yield a
fluorescent product that can be detected; and, (2) U.S. Pat. No.
6,762,280 by Schmidt et al. wherein assays for the proteolytic
activity of clostridal neurotoxins are described involving
synthetic peptide substrates modified with signal moieties such as
fluorescent molecules for eventual signal output by a proteolytic
product. Shine et al. describe still another fluorescence based
detection method for botulinum neurotoxins in U.S. Pat. No.
6,504,006. Fluorescence arrays can however produce fluorescence
response from unspecific cleavage of the substrate by other
proteases than clostridal toxins.
Applicants have now developed a detection and differentiation
method for botulinum neurotoxins based upon mass spectroscopy
analysis of proteolytic products. The method can also allow for
quantification of amounts of toxin and unequivocal product
identification due to specific botulinum toxin cleavage of
substrate.
It is an object of the present invention to provide such a
detection and differentiation method for botulinum neurotoxins.
SUMMARY OF THE INVENTION
In accordance with the purposes of the present invention, as
embodied and broadly described herein, the present invention
provides a method for detecting the presence of botulinum
neurotoxins in a sample including mixing a sample with a peptide
that can serve as a substrate for proteolytic activity of a
botulinum neurotoxin, and measuring for proteolytic activity of a
botulinum neurotoxin by a mass spectroscopy technique. In one
embodiment, the method can further provide a quantification or
determination of the amount of toxin present.
The present invention further provides a method for detecting the
presence of botulinum neurotoxins in a sample and differentiating
among types of botulinum neurotoxins, the process including mixing
a sample with a peptide that can serve as a substrate for
proteolytic activity of a botulinum neurotoxin, and measuring for
proteolytic activity of a botulinum neurotoxin by a mass
spectroscopy technique
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows the mass spectroscopy data for both: (a) a sample of a
specific peptide; and (b) a sample of the specific peptide after
mixing with a sample of BoNT serotype A.
FIG. 2 shows four peptides: (1) Substrate
1-Biotin(.epsilon.)-KGSNRTRIDEANQRATRMLGGK-(.epsilon.)Biotin (SEQ
ID NO: 1); (2) Substrate 14 -LSELDDRADALQAGASQFETSAAKLKRKYWWKNLK
(SEQ ID NO: 14); (3) Substrate
21-AQVDEVVDIMRVNVDKVLERDQKLSELDDRADALQAGAS (SEQ ID NO: 21); and (4)
Substrate 28-IIGNLRHMALDMGNEIDTQNRQIDRIMEKAD (SEQ ID NO: 28), at 1
nmole each in BoNT- reaction buffer containing 0.05 M Hepes pH 7.3,
25mM DTT, 20 mM ZnCl.sub.2, and 1 mg/ml BSA were spiked with BoNT-A
(A), BoNT-B (B), BoNT-C (C), BoNT-D (D), BoNT-E (E), BoNT-F (F),
dH.sub.2O for no toxin (G), BoNT-A and BoNT-B (H). The toxins were
spiked at 200 ng and incubated for 2 hours at 37.degree. C. Each
reaction (1 .mu.l) was spiked into 9 .mu.l of 5 mg/ml
alpha-cyano-4-hydroxy-cinnamic acid in 50% acetonitrile, 0.1% TFA,
1 mM ammonium citrate, then spotted in triplicate onto a MALDI
plate. Mass spectra were obtained by MALDI-TOF MS over the
mass/charge (m/z) range from 650 to 4500. The inset mass spectra
for BoNT-E distinguishes the NT-BoNT-E product from the BoNT-A
substrate.
FIG. 3 depicts an LC-ESI-MS/MS calibration curve for quantitation
of CT (C-terminus) and NT (N-terminus) peptides resulting from
cleavage of a substrate by the BoNT-A serotype of the clostridial
neurotoxin, as described herein. The x-axis represents the
concentration of the BoNT-A-substrate complex and the y-axis
represents the calculated concentration of the cleaved
peptides.
DETAILED DESCRIPTION
The present invention is concerned with mass spectrometry-based
methods for detection of botulinum neurotoxins (BoNTs). Further,
the present invention is concerned with mass spectrometry-based
methods for detection and differentiation among botulinum
neurotoxins (BoNTs). The method can further provide a
quantification or determination of the amount of toxin and serotype
present.
In the past few years, mass spectrometry (MS)-based methods have
emerged as fast and accurate tools to detect and identify a wide
range of biomarkers.
A rapid and accurate method for the detection and differentiation
of BoNTs has now been developed which utilizes the high specificity
of the enzymatic toxin with the high specificity of mass
spectroscopy (MS). This MS-based method allows the detection of
enzymatic activity of all the BoNT serotypes and those include the
A, B, E and F serotypes that are the serotypes of most interest due
to their potential threat to humans.
This MS-based method can be extended to other proteolytic cleavage
proteins within the Clostridium family as well as to tularemia.
Synthetic peptide substrates have been developed for the specific
endopeptidase activities of BoNTs, based on the sequences of the
natural protein substrates SNAP-25 (a synaptosome-associated
protein) and VAMP-2 (a vesicle-associated membrane protein). Since
each BoNT serotype has a unique cleavage site on a unique peptide,
specific product peptides can de detected by mass spectrometry and
differentiate among the active BoNT serotypes. In the method of the
present invention, a target sample can be mixed with the peptide
serving as a substrate for proteolytic activity of a botulinum
neurotoxin. After a digestion period of from a few minutes to a few
hours, preferably from about 30 minutes to about 2 hours, the
product peptides (both an N-terminated fragment and a C-terminated
fragment) can be recovered from any matrix using affinity tags on
the substrate peptide and therefore unequivocally identified and
quantified by mass spectroscopy.
Suitable mass spectrometry techniques can include matrix-assisted
laser desorption-ionization time of flight mass spectrometry
(MALDI-TOF-MS) and high performance liquid
chromatography-electrospray ionization-tandem mass spectrometry
(LC-ESI-MS/MS). Other mass spectroscopy techniques may also be
employed for analysis of the BoNT product peptides. MS-based
techniques such as MALDI-TOF-MS can allow screening of hundreds of
samples per hour for BoNT enzymatic activity. While LC-ESI-MS/MS is
much slower than MALDI-TOF-MS, it still offers high specificity and
sensitivity and allows accurate quantitative measurements of the
levels of BoNT. The MALDI-TOF-MS screening method has been used to
detect specific fragments of peptides cleaved by BoNT A, B, E and F
in a pure reaction buffer or within various environmental and
clinical type matrices such as milk, sausage, serum and stool
spiked with A, B and E light chain (about 50 kDa) and A and F toxin
complexes (about 500 and 900 kDa respectively).
The high specificity of the present invention has been verified by
testing a mixture of the substrate peptides with each of the BoNT
serotypes. In each case, only the specific and expected products
from the particular serotype were detected. An assay using the
method of the present invention could detect activity as low as 5
picograms per milliliter (pg/ml) of toxin in total sample volumes
of about 20 microliters. The present method has been demonstrated
to be fast, sensitive and specific and can be used as a
high-throughput assay for the detection and quantification of BoNT
activity in a variety of sample types.
Within various embodiments of the present invention, the substrate
can be any peptide or protein that can serve as a substrate for the
proteolytic activity of the target neurotoxin, especially the
clostridial neurotoxins. Among suitable substrates are substrates
similar to those described by Schmidt et al. in U.S. Pat. No.
6,762,280, in particular, the substrates described in columns 5-8
with the exception that signal (fluorescence) labels such as the
S-(fluoresceinyl)-cysteine and quenching labels such as
N(epsilon)-(2,4-dinitrophenyl)-lysine are unnecessary and can be
any suitable amino acid that leaves the cleavage site unaffected.
The substrates as described by Schmidt et al. in those columns are
hereby incorporated by reference. In a substrate of the present
invention, a final substrate (1)
Biotin-KGSNRTRIDEANQRATRMLGGK-biotin was constructed. Substrate (1)
(SEQ ID NO: 1) included the following peptide with biotin bound at
both ends of the peptide:
TABLE-US-00001 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 K G
S N R T R I D E A N Q R A T R M L 20 21 22 G G K.
The cleavage site remains the same as in substrate (1) of Schmidt
et al. at column 5.
Other substrates for BoNT A and BoNT C were constructed and
included substrate (2) BiotinKG SNRTRIDQGNQRATRNleLGGKBiotin (SEQ
ID NO: 2), substrate 3 BiotinKGSNRTR(I+7)DQGNQR(A+7)TRNleLGGKBiotin
(SEQ ID NO: 3), substrate 4 BiotinKGSNRTRIDEGNQRATRNleLGGKBiotin
(SEQ ID NO: 4), and substrate 5
BiotinKGSNRTR(I+7)DEGNQR(A+7)TRNleLGGKBiotin (SEQ ID NO: 5).
Examples of non-biotinylated substrates for BoNT A and BoNT C can
include substrate 6 SNKTRIDEANQRATKML (SEQ ID NO: 6), substrate 7
SNRTRIDQGNQRATRML (SEQ ID NO: 7), substrate 8 NRTRIDQGNQRGTRML (SEQ
ID NO: 8), substrate 9 SNRTRIDQANRQATRML (SEQ ID NO: 9), substrate
10 SNRTRIDQANQRATRNleL (SEQ ID NO: 10), substrate 11
SNRTRIDEGNQRATRNleL (SEQ ID NO: 11), and substrate 12
SNRTRIDQGNQRGTRNleL (SEQ ID NO: 12). Substrate (2) (SEQ ID NO: 2)
included the following peptide with biotin bound at both ends of
the peptide:
TABLE-US-00002 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
21 22 K G S N R T R I D Q G N Q R A T R M L G G K
In this substrate at 18, Norleucine (Nle) is substituted for
Methionine (M),
TABLE-US-00003 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
21 22 (SEQ ID NO: 58). K G S N R T R I D Q G N Q R A T R Nle L G G
K
Substrate (3) (SEQ ID NO: 3) included the following peptide with
biotin bound at both ends of the peptide:
TABLE-US-00004 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
21 22 K G S N R T R (I+7) D Q G N Q R (A+7) T R M L G G K
In this substrate at 18, Norleucine is substituted for
Methionine,
TABLE-US-00005 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
21 22 (SEQ ID NO: 59). K G S N R T R (I+7) D Q G N Q R (A+7) T R
Nle L G G K
Substrate (4) (SEQ ID NO: 4) included the following peptide with
biotin bound at both ends of the peptide:
TABLE-US-00006 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
21 22 K G S N R T R I D E G N Q R A T R M L G G K
In this substrate at 18, Norleucine is substituted for
Methionine,
TABLE-US-00007 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
21 22 (SEQ ID NO: 60). K G S N R T R I D E G N Q R A T R Nle L G G
K
Substrate (5) (SEQ ID NO: 5) included the following peptide with
biotin bound at both ends of the peptide:
TABLE-US-00008 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
21 22 K G S N R T R (I+7) D E G N Q R (A+7) T R M L G G K
In this substrate at 18, Norleucine is substituted for
Methionine,
TABLE-US-00009 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
21 22 (SEQ ID NO: 61). K G S N R T R (I+7) D E G N Q R (A+7) T R
Nle L G G K
Substrate (6) (SEQ ID NO: 6) included the following peptide:
TABLE-US-00010 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 S N K T R
I D E A N Q R A T K M L
Substrate (7) (SEQ ID NO: 7) included the following peptide:
TABLE-US-00011 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 S N R T R
I D Q G N Q R A T R M L
Substrate (8) (SEQ ID NO: 8) included the following peptide:
TABLE-US-00012 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 S N R T R
I D Q G N Q R G T R M L
Substrate (9) (SEQ ID NO: 9) included the following peptide:
TABLE-US-00013 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 S N R T R
I D Q A N R Q A T R M L
Substrate (10) (SEQ ID NO: 10) included the following peptide:
TABLE-US-00014 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 S N R T R
I D Q A N Q R A T R M L
In this substrate at 16, Norleucine is substituted for
Methionine,
TABLE-US-00015 (SEQ ID NO: 62). 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
16 17 S N R T R I D Q A N Q R A T R Nle L
Substrate (11) (SEQ ID NO: 11) included the following peptide:
TABLE-US-00016 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 S N R T R
I D E G N Q R A T R M L
In this substrate at 16, Norleucine is substituted for
Methionine,
TABLE-US-00017 (SEQ ID NO: 63). 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
16 17 S N R T R I D E G N Q R A T R Nle L
Substrate (12) (SEQ ID NO: 12) included the following peptide:
TABLE-US-00018 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 S N R T R
I D Q G N Q R G T R M L
In this substrate at 16, Norleucine is substituted for
Methionine,
TABLE-US-00019 (SEQ ID NO: 64). 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
16 17 S N R T R I D Q G N Q R G T R Nle L
TABLE-US-00020 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 K G
S N R T R I D Q G N Q R A T R M L 20 21 22 G G K
In this substrate at 18, Norleucine (Nle) is substituted for
Methionine (M). Substrate (3) (SEQ ID NO: 3) included the following
peptide with biotin bound at both ends of the peptide:
TABLE-US-00021 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 K G S N R T R
(I + 7) D Q G N Q R (A + 7) T 17 18 19 20 21 22 R M L G G K
In this substrate at 18, Norleucine is substituted for Methionine.
Substrate (4) (SEQ ID NO: 4) included the following peptide with
biotin bound at both ends of the peptide:
TABLE-US-00022 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 K G
S N R T R I D E G N Q R A T R M L 20 21 22 G G K
In this substrate at 18, Norleucine is substituted for Methionine.
Substrate (5) (SEQ ID NO: 5) included the following peptide with
biotin bound at both ends of the peptide:
TABLE-US-00023 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 K G S N R T R
(I + 7) D E G N Q R (A + 7) T 17 18 19 20 21 22 R M L G G K
In this substrate at 18, Norleucine is substituted for Methionine.
Substrate (6) (SEQ ID NO: 6) included the following peptide:
TABLE-US-00024 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 S N K T R
I D E A N Q R A T K M L
Substrate (7) (SEQ ID NO: 7) included the following peptide:
TABLE-US-00025 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 S N R T R
I D Q G N Q R A T R M L
Substrate (8) (SEQ ID NO: 8) included the following peptide:
TABLE-US-00026 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 S N R T R
I D Q G N Q R G T R M L
Substrate (9) (SEQ ID NO: 9) included the following peptide:
TABLE-US-00027 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 S N R T R
I D Q A N R Q A T R M L
Substrate (10) (SEQ ID NO: 10) included the following peptide:
TABLE-US-00028 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 S N R T R
I D Q A N Q R A T R M L
In this substrate at 16, Norleucine is substituted for Methionine.
Substrate (11) (SEQ ID NO: 11) included the following peptide:
TABLE-US-00029 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 S N R T R
I D E G N Q R A T R M L
In this substrate at 16, Norleucine is substituted for Methionine.
Substrate (12) (SEQ ID NO: 12) included the following peptide:
TABLE-US-00030 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 S N R T R
I D Q G N Q R G T R M L
In this substrate at 16, Norleucine is substituted for
Methionine.
Stable isotope labels (.sup.13C.sub.6, .sup.15N) Isoleucine and/or
(.sup.13C.sub.3, .sup.2H.sub.3, .sup.15N) Alanine were incorporated
as Fmoc protected derivatives into the solid phase synthesis of the
peptides. Exemplary of such labeled materials for internal isotope
references are the pairs of SNRTRIDQGNQ (SEQ ID NO: 54) and
SNRTR(I+7)DQGNQ (SEQ ID NO: 56) (for isoleucine) and RATRNleL SEQ
NO: 55) and R(A+7)TRNleL (SEQ ID NO: 57) (for alanine). Other
references can readily be prepared as needed. Use of isotope
dilution spectroscopy and internal isotope references allow the
calibration of the mass spectrometry method and contribute to
dramatically improve the sensitivity of the detection method. The
labeling position as well as the labeling pattern shown in the
example are non-exclusive; other positions and other labeling
patterns could be employed to achieve the mass differences suited
for isotope dilution spectroscopy and internal isotope
references.
Examples of a substrate for a BoNT B include: substrate (13)
Biotin-KG-LSELDDRADALQAGASQFETSAAKLKRKYWWKNLGGK-Biotin (SEQ ID NO:
13) and non-biotinylated substrate (14)
LSELDDRADALQAGASQFETSAAKLKRKYWWKNLK (SEQ ID NO: 14). Substrate (13)
(SEQ ID NO: 13) included the following peptide with biotin bound at
both ends of the peptide:
TABLE-US-00031 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 K
G L S E L D D R A D A L Q A G A S Q F 21 22 23 24 25 26 27 28 29 30
31 32 33 34 35 E T S A A K L K R K Y W W K N 36 37 38 39 L G G
K.
Substrate (14) (SEQ ID NO: 14) included the following peptide:
TABLE-US-00032 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 L S
E L D D R A D A L Q A G A S Q F E 20 21 22 23 24 25 26 27 28 29 30
31 32 33 34 35 T S A A K L K R K Y W W K N L K.
Other isotope standard pairs employed to calibrate and refine the
method can include: substrate (15) LSELDDRADALQAGASQ (SEQ ID NO:
15), substrate (16) LSELDDR(A+7)DALQAGASQ (SEQ ID NO: 16),
substrate (17) LSELDDRADALQAGAS (SEQ ID NO: 17), substrate (18)
LSELDDR(A+7)DALQAGAS (SEQ ID NO: 18), substrate (19)
FETSAAKLKRKYWWKNLK (SEQ ID NO: 19) and substrate (20)
FETS(A+7)AKLKRKYWWKNLK (SEQ ID NO: 20). Substrate (15) (SEQ ID NO:
15) included the following peptide:
TABLE-US-00033 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 L S E L D
D R A D A L Q A G A S Q
Substrate (16) (SEQ ID NO: 16) included the following peptide:
TABLE-US-00034 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 L S E L D
D R (A + 7) D A L Q A G A S Q
Substrate (17) (SEQ ID NO: 17) included the following peptide:
TABLE-US-00035 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 L S E L D D R
A D A L Q A G A S.
Substrate (18) (SEQ ID NO: 18) included the following peptide:
TABLE-US-00036 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 L S E L D D R
(A + 7) D A L Q A G A S.
Substrate (19) (SEQ ID NO: 19) included the following peptide:
TABLE-US-00037 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 F E T S
A A K L K R K Y W W K N L K
Substrate (20) (SEQ ID NO: 20) included the following peptide:
TABLE-US-00038 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 F E T S
(A + 7) A K L K R K Y W W K N L K.
An example of a substrate for BoNT D and BoNT F includes: substrate
(21) AQVDEVVDIMRVNVDKVLERDQKLSELDDRADALQAGAS (SEQ ID NO: 21).
Isotope standards employed to calibrate and refine the method
included: substrate (22) KLSELDDRADALQAGAS (SEQ ID NO: 22),
substrate (23) KLSELDDR(A+7)DALQAGAS (SEQ ID NO: 23), substrate
(24) AQVDEVVDIRVNVDKVLERDQ (SEQ ID NO: 24), substrate (25) (A+7)
QVDEVVDIMRVNVDKVLERDQ (SEQ ID NO: 25), substrate (26)
AQVDEVVDIMRVNVDKVLERDQK (SEQ ID NO: 26), and substrate (27) (A+7)
QVDEVVDIMRVNVDKVLERDQK (SEQ ID NO: 27).
Substrate (21) (SEQ ID NO: 21) included the following peptide:
TABLE-US-00039 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 A Q
V D E V V D I M R V N V D K V L E 20 21 22 23 24 25 26 27 28 29 30
31 32 33 34 35 R D Q K L S E L D D R A D A L Q 36 37 38 39 A G A
S.
Substrate (22) (SEQ ID NO: 22) included the following peptide:
TABLE-US-00040 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 K L S E L
D D R A D A L Q A G A S
Substrate (23) (SEQ ID NO: 23) included the following peptide:
TABLE-US-00041 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 K L S E L
D D R (A + 7) D A L Q A G A S
Substrate (24) (SEQ ID NO: 24) included the following peptide:
TABLE-US-00042 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 1718 19 A Q V
D E V V D I M R V N V D K V L E 20 21 22 R D Q
Substrate (25) (SEQ ID NO: 25) included the following peptide:
TABLE-US-00043 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 (A + 7)
Q V D E V V D I M R V N V D K V L 19 20 21 22 E R D Q
Substrate (26) (SEQ ID NO: 26) included the following peptide:
TABLE-US-00044 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 A Q
V D E V V D I M R V N V D K V L E 20 21 22 23 R D Q K
Substrate (27) (SEQ ID NO: 27) included the following peptide:
TABLE-US-00045 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 (A + 7)
Q V D E V V D I M R V N V D K V L 19 20 21 22 23 E R D Q K.
An example of a substrate for BoNT E includes: substrate (28)
IIGNLRHMALDMGNEIDTQNRQIDRIMEKAD (SEQ ID NO: 28). Isotope standards
employed to calibrate and refine the method included: substrate
(29) IIGNLRHMALDMGNEIDTQNRQIDR (SEQ ID NO: 29), substrate (30)
IIGNLRHM(A+7)LDMGNEIDTQNRQIDR (SEQ ID NO: 30), substrate (31)
IMEKAD (SEQ ID NO: 31), and substrate (32) IMEK(A+7)D (SEQ ID NO:
32). Substrate (28) (SEQ ID NO: 28) included the following
peptide:
TABLE-US-00046 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 I I
G N L R H M A L D M G N E L D T Q 20 21 22 23 24 25 26 27 28 29 30
31 N R Q I D R I M E K A D
Substrate (29) (SEQ ID NO: 29) included the following peptide:
TABLE-US-00047 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 I I
G N L R H M A L D M G N E L D T Q 20 21 22 23 24 25 N R Q I D
R.
Substrate (30) (SEQ ID NO: 30) included the following peptide:
TABLE-US-00048 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 I I G N
L R H M (A + 7) L D M G N E I D T 19 20 21 22 23 24 25 Q N R Q I D
R.
Substrate (31) (SEQ ID NO: 31) included the following peptide:
TABLE-US-00049 1 2 3 4 5 6 I M E K A D .
Substrate (32) (SEQ ID NO: 32) included the following peptide:
TABLE-US-00050 1 2 3 4 5 6 I M E K (A + 7) D .
Examples of substrates for BoNT G include: substrate (33)
IEYNVEHAVDYVERAVSDTKKAVKYQSKARRKKINleI, substrate (34)
IEYNVEHAVDYVERAVSDTKKAVRYQSKARRKKINleI, substrate (35)
IEYNVEHAVDYVERAVSQTKKAVRYQSKARRKKINleI, and substrate (36)
IEYNVEHAVDYVERAVSQSKKAVRYQSKARRKKINleI. Substrate (33) (SEQ ID NO:
33) included the following peptide:
TABLE-US-00051 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 I E
Y N V E H A V D Y V E R A V S D T 20 21 22 23 24 25 26 27 28 29 30
31 32 33 K K A V K Y Q S K A R R K K 34 35 36 I NIe I.
In this substrate at 35, Norleucine is substituted for
Methionine,
TABLE-US-00052 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
21 22 23 24 25 26 27 (SEQ ID NO: 65). I E Y N V E H A V D Y V E R A
V S D T K K A V K Y Q S 28 29 30 31 32 33 34 35 36 K A R R K K I
Nle I
Substrate (34) (SEQ ID NO: 34) included the following peptide:
TABLE-US-00053 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 I E
Y N V E H A V D Y V E R A V S D T 20 21 22 23 24 25 26 27 28 29 30
31 32 33 K K A V R Y Q S K A R R K K 34 35 36 I M I.
In this substrate at 35, Norleucine is substituted for
Methionine,
TABLE-US-00054 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
21 22 23 24 25 26 27 (SEQ ID NO: 66). I E Y N V E H A V D Y V E R A
V S D T K K A V R Y Q S 28 29 30 31 32 33 34 35 36 K A R R K K I
Nle I
Substrate (35) (SEQ ID NO: 35) included the following peptide:
TABLE-US-00055 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 I E
Y N V E H A V D Y V E R A V S Q T 20 21 22 23 24 25 26 27 28 29 30
31 32 33 K K A V R Y Q S K A R R K K 34 35 36 I M I.
In this substrate at 35, Norleucine is substituted for
Methionine,
TABLE-US-00056 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
21 22 23 24 25 26 27 (SEQ ID NO: 67). I E Y N V E H A V D Y V E R A
V S Q T K K A V R Y Q S 28 29 30 31 32 33 34 35 36 K A R R K K I
Nle I
Substrate (36) (SEQ ID NO: 36) included the following peptide:
TABLE-US-00057 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 I
E Y N V E H A V D Y V E R A V S Q S K 21 22 23 24 25 26 27 28 29 30
31 32 33 34 35 36 K A V R Y Q S K A R R K K I M I.
In this substrate at 35, Norleucine is substituted for
Methionine,
TABLE-US-00058 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
21 22 23 24 25 26 27 (SEQ ID NO: 68). I E Y N V E H A V D Y V E R A
V S Q S K K A V R Y Q S 28 29 30 31 32 33 34 35 36 K A R R K K I
Nle I
Amides of the BoNT substrates, which can be more stable towards C
terminal degradation in solution, are easily incorporated into the
assay. Examples include substrate (37) SNKTRIDEANQRATKML-amide (SEQ
ID NO: 37) and substrate (38) SNRTRIDEANQRATRML-amide (SEQ ID NO:
38). Substrate (37) (SEQ ID NO: 37) included the following peptide
with amide bound at one end of the peptide:
TABLE-US-00059 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 S N K T R
I D E A N Q R A T K M L.
Substrate (38) (SEQ ID NO: 38) included the following peptide with
amide bound at one end of the peptide:
TABLE-US-00060 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 S N R T R
I D E A N Q R A T R M L.
MAP.sub.4 like tree structures have been synthesized and shown to
increase the specific turnover, over unspecific protease background
cleavage reactions, for example, substrate (39)
(SNRTRIDQGNQRATRNleL)4K2KC(beta)A (SEQ ID NO: 39), a Lysine
MAP.sub.4 tree. Substrate (39) (SEQ ID NO: 39) included the
following peptide with a lysine MAP.sub.4 structure tree bound at
the C-end of the peptide:
TABLE-US-00061 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 S N R T R
I D Q G N Q R A T R M L.
In this substrate at 16, Norleucine is substituted for
Methionine,
TABLE-US-00062 (SEQ ID NO: 69). 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
16 17 S N R T R I D Q G N Q R A T R Nle L
Peptide sequences for the BoNT endoproteinase assay are listed in
Table 1 along with the predicted cleavage products for each
serotype, and masses associated with the substrate and cleaved
product peptides. Superscript letters in the sequence denote the
cleavage site for the serotype, e.g., .sup.a=BoNT-A. The peptides
for BoNT-A, -C, and -E were derived from the human SNAP-25 protein.
The BoNT-A/-C substrate (1) has modifications from the native human
SNAP-25 sequence (187-substrate 37-203) for the BoNT-A/-C substrate
of biotin(.epsilon.)-KG(K.sub.189->R and
K.sub.201->R)GGK-(.epsilon.)Biotin. The BoNT-E substrate
sequence (2) was also from human SNAP-25 (156-186). The substrate
peptides for BoNT-B, -D, and -F are from human synaptobrevin 2; the
BoNT-B substrate (3) is from 59-93 in the sequence and the
BoNT-D/-F substrate is from 35-74.
TABLE-US-00063 TABLE 1 Substrates and Corresponding Fragments
Botulinum Neurotoxin Specific Peptide Substrates Mass BoNT-A, -C
Biotin-KGSNRTRIDEANQ.sup.aR.sup.cATRMLGGK-Biotin (Substrate 1)
2912.6 NT-BoNT-A Product Biotin-KGSNRTRIDEANQ.sup.a 1713.8
GT-BoNT-A Product .sup.aRATRMLGGK-Biotin 1215.3 NT-BoNT-C Product
Biotin-KGSNRTRIDEANQR.sup.c 1871.0 CT-BoNT-C Product
.sup.cATRMLGGK-Biotin 1059.6 BoNT-E
IIGNLRHMALDMGNEIDTQNRQIDR.sup.eIMEKAD (Substrate 28) 3612.1
NT-BoNT-E Product IIGNLRHMALDMGNEIDTQNRQIDR.sup.e 2924.3 CT-BoNT-E
Product .sup.eIMEKAD 705.8 BoNT-B
LSELDDRADALQAGASQ.sup.bFETSAAKLKRKYWWKNLK 4039.6 (Substrate 14)
NT-BoNT-B Product LSELDDRADALQAGASQ.sup.b 1759.8 CT-BoNT-B Product
.sup.bFETSAAKLKRKYWWKNLK 2297.7 BoNT-D, -F
AQVDEVVDIMRVNVDKVLERDQ.sup.fK.sup.dLSELDDRADALQAGAS 4312.8
(Substrate 21) CT-BoNT-D Product AQVDEVVDIMRVNVDKVLERDQK.sup.d
2699.1 NT-BoNT-D Product .sup.dLSELDDRADALQAGAS 1631.7 NT-BoNT-F
Product AQVDEVVDIMRVNVDKVLERDQ.sup.f 2570.9 GT-BoNT-F Product
.sup.fKLSELDDRADALQAGAS 1759.9 Internal Standard
LRTAQADITNSK-(.epsilon.) Biotin 1542.78 BoNT-A SNRTRIDQGNQRATRXL (X
= norleucine) (Substrate 40) 1998.3 NT-BoNT-A Product SNRTRIDQGNQ
1288.3 CT-BoNT-A Product RATRXL 729.5
(SEQ ID NO: 40) Fragment 1 from Substrate 1, KGSNRTRIDEANQ.
Fragment 1 includes Biotin that is bound at the first terminous of
the protein fragment. (SEQ ID NO: 41) Fragment 2 from Substrate 1,
RATRMLGGK. Fragment 2 includes Biotin that is bound at no. 9 of the
protein fragment. (SEQ ID NO: 42) Fragment 3 from Substrate 1,
KGSNRTRIDEANQR Fragment 3 includes Biotin that is bound at the
first terminous of the protein fragment. (SEQ ID NO: 43) Fragment 4
from Substrate 1, ATRMLGGK. Fragment 4 includes Biotin that is
bound at no. 8 of the protein fragment. (SEQ ID NO: 44) Fragment 5
from Substrate 28, IIGNLRHMALDMGNEIDTQNRQIDR. (SEQ ID NO: 45)
Fragment 6 from Substrate 28, IMEKAD. (SEQ ID NO: 46) Fragment 7
from Substrate 14, LSELDDRADALQAGASQ. (SEQ ID NO: 47) Fragment 8
from Substrate 14, FETSAAKLKRKYWWKNLK. (SEQ ID NO: 48) Fragment 9
from Substrate 21, AQVDEVVDIMRVNVDKVLERDQK. (SEQ ID NO: 49)
Fragment 10 from Substrate 21, LSELDDRADALQAGAS. (SEQ ID NO: 50)
Fragment 11 from Substrate 21, AQVDEVVDIMRVNVDKVLERDQ. (SEQ ID NO:
51) Fragment 12 from Substrate 21, KLSELDDRADALQAGAS. (SEQ ID NO:
52) LRTAQADITNSK. Biotin is bound at no. 12 of the protein
fragment. (SEQ ID NO: 53) Substrate 40, SNRTRIDQGNQRATRXL.
(X=norleucine) (SEQ ID NO: 54) Fragment 13 from Substrate 40,
SNRTRIDQGNQ. (SEQ ID NO: 55) Fragment 14 from Substrate 40,
RATRXL.
Affinity tags such as biotin are attached on both sides of the
cleavage site on the substrate such that after cleavage the
products from the cleavage can be collected and separated from any
matrix and sample contaminants, as well as, from the toxins. The
recovery of both unreacted substrate and cleavage products can be
used for calibration and control experiment purposes.
The mass spectroscopy approach to analysis of the products allows a
quantification of the amount of neurotoxin since the ratio of the
products to the unreacted substrate can be determined, the length
of time of digestion will be known and the amount of starting
material, i.e., substrate, will be known so that a calibration
curve may be calculated and allow the quantification of the amount
of neurotoxin.
The ENDOPEP-MS reaction has proven to be very useful for detecting
small amounts of BoNT in a rapid, animal-free assay. This assay is
very effective when used as a 20 .mu.L reaction consisting of BoNT,
reaction buffer, and peptide substrate, with detection of the
cleavage of the peptide substrate through mass spectrometry.
However, there may be a need to perform this assay with clinical
samples in larger volumes (100 .mu.L to 1 mL) and such an
additional step may be preferred in those instances. Many food and
clinical samples contain abundant proteases which cleave the
peptide substrate, prohibiting the toxin from cleaving the
substrate. Therefore, it becomes necessary to pursue a method to
capture and concentrate BoNT from a larger volume (100 .mu.L to 1
mL) of a clinical or other type of sample. It has now been shown
that the use of antibodies is extremely effective at concentrating
the toxin while discarding proteases which have a detrimental
effect on the assay. In this method, antibody (Ab) is bound to
magnetic protein G beads which are then cross-linked to the beads
to ensure their attachment and proper orientation. It should be
noted that antibody platforms other than magnetic beads, such as
columns or pipette tips would also most likely work as well. After
washing the cross-linked Ab-coated beads, the beads are blocked
through the addition of casein buffer and a short incubation. Upon
removal of the casein buffer, toxin in a liquid matrix (buffer,
milk, serum, stool extract, food extract, or gastric extract) can
be added to the Ab-coated beads and incubated for 2 hours while the
toxin present in the sample binds to the Ab-coated beads and other
proteases do not. The beads can then be stringently washed with a
detergent-containing buffer followed by a water wash to dispose of
the detergent. At this point, the reaction buffer and the peptide
substrate are added to the Ab-coated beads for an incubation of
several hours. If toxin is present, the peptide substrate is
cleaved in a specific location, generating two product peptides.
These product peptides can then be detected through analysis by
mass spectrometry.
As noted, the ENDOPEP-MS reaction has proven to be very useful for
detecting small amounts of BoNT in a rapid, animal-free assay and
the assay is very effective when used as a 20 .mu.L reaction
consisting of BoNT, reaction buffer, and peptide substrate, with
detection of the cleavage of the peptide substrate through mass
spectrometry. However, when working with clinical or food samples,
there are abundant proteases which cleave either the peptide
substrate or other proteases, producing a large number of
uninteresting peptides. Because mass spectrometers detect peptides
based on their ionization efficiencies, it is critical to analyze a
sample which preferentially contains an enriched sample of the
peptides of interest in order for those peptides to ionize at their
optimum level. Therefore, an affinity method of selecting for the
peptides generated from the cleavage of the peptide substrate by
BoNT may be preferentially used for ultimate detection in complex
biological samples. Biotinylated peptides have been used in
conjunction with avidin affinity chromatography to purify the
peptides prior to the mass spectrometric analysis. It should be
noted that other tagging platforms could be used here as well such
as, e.g., fluorous tagged peptides (a peptide tagged with a
fluorous compound such as those described, e.g., in U.S. Pat. No.
6,803,475); however, the avidin-biotin bond was chosen as it is one
of the strongest bonds in biology. Conditions were optimized on
synthetic product peptides using avidin columns, although it should
be noted that other avidin-biotin platforms could be used as well,
such as biotinylated peptides with avidin-coated beads. The
reactions with BoNT and the biotinylated peptides were allowed to
proceed from 4 to 24 hours and the reaction mixtures were diluted
in buffer and applied to the avidin columns. The bound substrate
and product peptides were then eluted. This procedure works very
well to clean-up the product peptides of interest from complex
matrices.
The peptide substrates used in the present method were designed to
be the same as the sequences of those portions of the natural
SNAP-25 (for BoNT A and E) or VAMP (for BoNT B and F) that are
recognized and cleaved, except some modifications were made in the
substrate peptide for BoNT A. Other modifications allowing better
stability may be conducted as well. For BoNT A the peptide from
SNAP-25 that includes serine-187 to glycine-206 is required for
cleavage at glutamine-196. James Schmidt et al., Appl. Env.
Microbiol., v. 69(1), pp. 297-303 (2003) previously found that
certain modifications to the natural sequence of this
SNAP-25-derived peptide showed enhanced cleavage by BoNT A.
Modifications that enhanced cleavage by BoNT A included replacing
lysines 189 and 201 with arginines. This modification was made to
the substrate peptide for BoNT A and resulted in an increase in the
amount of BoNT-dependent cleavage products detected, over that
observed with an unmodified SNAP-25 based peptide. The portion of
VAMP-2 that is required for cleavage by BoNT B at glutamine-75 is
leucine-59 to lysine 93 and the portion required for cleavage by
BoNT F at glutamine-57 is from alanine-36 to serine-74. The portion
of SNAP-25 from isoleucine-156 to aspartic acid-186 is required for
cleavage between arginine-180 and isoleucine-181 by BoNT E.
Possible modifications to the substrate peptides for B, E and F are
being explored that may enhance BoNT cleavage. The N and C terminus
of the substrate peptide for BoNT A have also been biotinylated so
that the product peptides of interest can be easily purified from
complex matrices. After final peptide sequences are determined, all
of the substrate peptides may be biotinylated or derivatized by
other suitable affinity tags for specific application
requirements.
The method was multiplexed by combining all four substrate peptides
for the BoNT serotypes A, B, E, and F into a sample that contained
various levels of a single BoNT serotype or no toxin. The samples
were incubated for 2 hours and the resulting peptides were measured
by either MALDI-TOF-MS or LC/ESI/MS/MS. The expected product
peptide masses along with the masses of the substrate peptides are
shown in FIG. 2. The product peptides for each specific BoNT
serotype can be easily distinguished by their mass. Typical results
for each of the reaction mixtures containing the four substrate
peptides incubated with only the reaction buffer (a blank) or with
one of the BoNT serotypes showed that each of the BoNT serotypes
only yielded the expected cleavage products from their respective
substrate peptides indicating that this method can easily detect
and differentiate active BoNT serotypes.
The sensitivity of the method was also tested. For BoNT A, B, and
F, as little as 0.01 mouse LD.sub.50 (about 0.1 pg active toxin) of
BoNT in a sample can yield sufficient quantities of product
peptides to be clearly detected by MALDI-TOF-MS. This is 100 times
lower than can be detected by the mouse bioassay. Additionally,
this small amount of toxin can be detected and the toxin type
differentiated in a single measurement. The mouse bioassay would
require separate mice for each of the toxin types to differentiate
the BoNT serotype.
This method is currently less sensitive for BoNT E than the other
serotypes. One mouse LD.sub.50 is required to clearly detect the
product peptides by MALDI-TOF-MS; however, the activity of BoNT E
can be enhanced by tryptic activation of the toxin. The Clostridium
botulinum strains that produce BoNT E lack the proteases that are
required to process the toxin into its highly active form. This
activation presumably occurs in vivo in individuals with botulism
from BoNT E. The mouse bioassay generally includes some
trypsin-activated samples in conjunction with non-activated samples
for injecting into the mouse. Additional work on this step in the
ENDOPEP-MS method may enhance the sensitivity of the method for
BoNT E.
The ENDOPEP-MS method has been applied to a variety of matrices
spiked with specific BoNT serotypes and also tested blank samples
that contain no BoNT. This method has been able to detect active
BoNT serotypes in all of the food and clinical samples which
include milk, yogurt, cheese, beef, sausage, serum, and stool. The
sensitivities in these matrices ranged from 0.01 in milk to 10
mouse LD.sub.50 in stool and meat. In these samples endogenous
proteases can diminish the amount of intact substrate peptides and
can destroy some of the intact product peptides. It is important to
note that no other proteases have been found in any matrix that
cleaves at the same site as the BoNT A, B, and F serotypes. The MS
detection method is so specific that the exact site of cleavage can
easily be determined. Thus, no false positives were obtained in any
of the matrices. Endogenous proteases merely diminish the absolute
sensitivity of the method. This level of specificity cannot easily
be obtained in any fluorescence-based detection system and false
positives would be expected with activity-based methods that employ
flourescence or flourigenic systems. Work continues on the use of
simple physical and chromatographic methods in combination with
cocktails of protease inhibitors to obtain the best sensitivity in
meat and stool samples; however, the amount of BoNT in a
contaminated meat or stool sample would likely be much higher than
10 mouse LD.sub.50, thus allowing detection with the present
method. Pre-assay enrichment of the botulinum toxins can further
enhance the selectivity over unspecific substrates.
The quantification of the amount of active BoNT in a sample is
important. MALDI-TOF-MS is very rapid and is appropriate for
relative quantification, but has limited capability for absolute
quantification since the spectra tend to show larger variations
than other mass spectral techniques. Thus, a LC-ESI/MS/MS technique
that can quantitatively detect and differentiate BoNT activities
has been developed. This method is highly specific, since correct
identification of the BoNT product peptides depends on both a
retention time match with respect to standards, and on a
chemical-specific fragmentation (a precursor to product ion
multiple reaction monitoring (MRM) transition) monitored by tandem
MS. To further enhance specificity, two separate MRM transitions
are monitored for each peptide. In addition, the LC-ESI/MS/MS
technique can be very sensitive, because it uses a triple
quadrupole-based instrument. Absolute quantification of the BoNT
product peptides is achieved using leucine enkephalin (any other
stable peptide which is neither a substrate nor an inhibitor of the
BoNT reaction may be used) as an internal standard to correct for
any instrumental variations. Typical LC-ESI/MS/MS chromatograms
were obtained during the quantification of the activity of BoNT A,
along with a standard curve for one of the product peptides. Based
on obtained data, it is estimated that it should be possible to
achieve absolute quantification to within less than 10-20% of the
true BoNT activity level. Identical LC-ESI/MS/MS strategies can be
used to quantify each of the BoNT serotypes. The amount of product
peptides produced in a BoNT reaction may be correlated to the
amount of active toxin in the sample.
The ENDOPEP-MS method has many possible applications. It was
developed for the rapid detection and differentiation of BoNT in
human clinical samples. Because it is rapid and sensitive, it could
also be used to test food samples for BoNT. Beyond using the
ENDOPEP-MS method for identifying the BoNT serotype in a clinical,
food or environmental sample, it may be possible to standardize
BoNT activity in samples used for clinical treatment or in research
activities. The standardization of BoNT, both the amount of 150 KDa
toxin and the activity of a standard solution, is of great
importance in the use of BoNT medically and in the search for
inhibitors of BoNT and treatments for botulism.
The present invention is more particularly described in the
following examples which are intended as illustrative only, since
numerous modifications and variations will be apparent to those
skilled in the art.
EXAMPLE 1
Peptidic substrates were obtained using standard solid state
peptide synthesis. A C-terminal biotin was obtained using a
commercial Lysine(K)-biotin resin (available from Advanced Chem.
Tech.) and standard solid state peptide synthesis conducted to
construct the desired substrate with the N-terminal biotin
introduced onto the peptide on a Boc-lysine (Fmoc) terminus after
deprotection of the sidechain using commercially available
activated biotin succinimide (available from NovaBiochem). In this
manner the peptidic substrate of
Biotin-KGSNRTRIDEANQRATRMLGGK-biotin (SEQ ID NO: 1) (Substrate 1)
was prepared.
EXAMPLE 2
An initial sample of the peptide
Biotin-KGSNRTRIDEANQRATRMLGGK-biotin (SEQ ID NO: 1) (Substrate 1)
was measured by MALDI-TOF-MS. The mass spectroscopy data of this
sample is shown in FIG. 1(a).
The sample of the peptide Biotin-KGSNRTRIDEANQRATRMLGGK-biotin (SEQ
ID NO: 1) (Substrate 1) was then mixed with a sample of BoNT
serotype A and the mixture was digested for two hours and the
peptide substrate and products were specifically absorbed on avidin
affinity columns, washed and then eluted with free biotin. The
collected sample was then analyzed by MALDI-TOF-MS. The mass
spectroscopy data of this sample is shown in FIG. 1(b). Two
distinct peptide products were shown that were the result of the
specific cleavage of the peptide. Excess biotin had a lower
molecular weight outside the range of this MS range. Quantification
of the amount of neurotoxin from the known quantities, time of
digestion and MS data indicated detection of activity as low as 5
pc/mL of toxin.
EXAMPLE 3
As noted, the ENDOPEP-MS reaction has proven to be very useful for
detecting small amounts of BoNT in a rapid, animal-free assay. The
use of antibodies in concentrating the toxin can be conducted as
follows.
Antibodies can be obtained from a variety of sources, e.g.,
Metabiologics (Madison, Wis.) supplies antibodies in a solution of
150 mM potassium phosphate, pH 7.4. The concentration for each
batch of antibody is different. Magnetic protein G beads can be
obtained from Dynal (Lake Success, N.Y.) at 1.3 g/cm.sup.3 and are
supplied in a solution of phosphate buffered saline (PBS), pH 7.4,
containing 0.1% Tween TWEEN.RTM.-20 (polyoxyethylene sorbitan
monolaurate)and 0.02% sodium azide. Triethanolamine and dimethyl
pimelimidate used for cross-linking can be obtained from
Sigma-Aldrich (St. Louis, Mo.). Casein buffer is comprised of 5 g
of casein (Sigma-Aldrich) dissolved in 500 mL of PBS
(Sigma-Aldrich). PBS-T buffer is comprised of PBS with 0.005% TWEEN
.RTM.-20 (Sigma-Aldrich). TBS buffer is comprised of Tris buffer
saline (50 mM Tris buffer with 10 mM NaCl at pH=7.5) obtained from
Sigma-Aldrich. Protease inhibitor cocktail is comprised of 5%
casein, 4.5 mg/mL of 4-(2-Aminoethyl)benzenesulfonyl fluoride
hydrochloride (AEBSF), 25 mg/mL of 6-Aminohexanoic acid, 3.15 mg/mL
of Antipain, and 20 mg/mL of
(2S,3S)-trans-Epoxysuccinyl-L-leucylamido-3-methylbutane ethyl
ester (E-64). All protease inhibitors can be obtained from
Sigma-Aldrich.
The manufacture of antibody-coated beads can be as follows. 1)
Transfer 100 .mu.L of protein G magnetic beads into a
microcentrifuge tube. 2) Place the tube on the magnet for 30
seconds and pipette off the supernatant. 3) Remove the tube from
the magnet and add 500 .mu.L of PBS buffer. Reconstitute the beads
so that a homogeneous solution is formed. 4) Repeat steps 3, 4, and
3. 5) Put 50 .mu.g of antibody into 500 .mu.L of PBS and add this
solution to the beads. 6) Incubate this mixture at room temperature
on a rotation device for several hours. 7) Place the tube with the
beads on the magnet for 30 seconds and pipette off the supernatant.
8) Remove the tube from the magnet and add 500 .mu.L of PBS buffer.
9) 10) Repeat steps 7 and 8 twice. 11) Place the tube on the magnet
and pipette off the supernatant. 12) Add 1 mL of triethanolamine
buffer to the beads. Reconstitute the beads so that a homogeneous
solution is formed. 13) Place the tube with the beads on the magnet
for 30 seconds and pipette off the supernatant. 14) Repeat steps 11
and 12. 15) Mix a solution of 5.4 mg of dimethyl pimelidate in 1 mL
of triethanolamine buffer. Add this solution to the beads. 16)
Incubate this mixture at room temperature on a rotation device for
30 minutes.
17) Place the tube with the beads on the magnet for 30 seconds and
pipette off the supernatant. 18) Re-suspend the beads in 1 mL of
TBS buffer and incubate for 15 minutes at room temperature on a
rotation device. 19) Place the tube on the magnet for 30 seconds
and pipette off the supernatant. 20) Reconstitute the beads in 500
.mu.L of PBS-T. 21) Repeat steps 18 and 19. 22) Place the tube on
the magnet for 30 seconds and pipette off the supernatant. 23)
Reconstitute the beads in 100 .mu.L of PBS-T and store until
needed. The capture of toxin with antibody-coated beads can be as
follows. 1) Prepare toxin-spiked sample by adding BoNT to liquid
sample and set aside.
2) Prepare beads for capture by using beads at 1/5 the volume of
the sample (e.g. if sample size is 500 .mu.L, use 100 .mu.L of
beads). 3) Add liquid toxin-spiked sample to the beads. 4) If
toxin-spiked sample is serum, stool extract, food extract, or
gastric extract, add protease inhibitor cocktail at 1/20 the volume
of the sample (e.g. if sample size is 500 .mu.L, use 25 .mu.L of
protease inhibitor cocktail). 5) Incubate at room temperature for 2
hours on a rotation device. 6) Place the tube with the beads on the
magnet for 30 seconds and pipette off the supernatant. 7) Add 500
.mu.L of PBS-T buffer to the beads and reconstitute them. 8) Repeat
steps 5 and 6 three times. 9) Place the tube with the beads on the
magnet for 30 seconds and pipette off the supernatant. 10) Add 500
.mu.L of water to the beads and reconstitute them. 11) Repeat steps
8 and 9. 12) Place the tube with the beads on the magnet for 30
seconds and pipette off the supernatant. 13) Reconstitute the beads
in 19 .mu.L of reaction buffer and 1 .mu.L of peptide substrate for
all samples other than stool extract. For stool extract samples,
add 16.5 .mu.L of reaction buffer, 1 .mu.L of peptide substrate,
and 2.5 .mu.L of protease inhibitor cocktail. 14) Incubate BoNT
reaction and analyze substrate cleavage by mass spectrometry of
supernatant.
EXAMPLE 4
As noted, the ENDOPEP-MS reaction has proven to be very useful for
detecting small amounts of BoNT in a rapid, animal-free assay. The
use of affinity chromatography in purifying the toxin can be
conducted as follows. This procedure worked very well to clean-up
the product peptides of interest from complex matrices.
All chemicals for this example were obtained from Sigma-Aldrich
(St. Louis, Mo.) unless otherwise noted. 1) Biotinylated peptides
were constructed using standard solid state peptide synthesis to
yield the desired substrate. 2) Avidin columns were obtained from
Applied Biosystems (Foster City, Calif.) as a portion of the ICAT
kit. It should be noted that avidin columns from other sources
could be used as well. 3) Load buffer is phosphate buffered saline
(PBS) at a 2.times. concentration, diluted from a 10.times.
concentration, which is 100 mM sodium phosphate, 9% NaCl, pH=7.4.
4) Wash #1 buffer is PBS at a 1.times. concentration, diluted from
a 10.times. concentration. 5) Wash #2 buffer is 50 mM ammonium
bicarbonate, 20% methanol. 6) Elution buffer is 30% acetonitrile
and 0.4% trifluoroacetic acid (TFA) 7) Storage buffer is PBS at
1.times. concentration with 0.1% sodium azide. 8) Matrix solution
is alpha-cyano-4-hydroxy cinnamic acid (CHCA) at 5 mg/mL in 50%
acetonitrile, 0.1% TFA, and 1 mM ammonium citrate The purification
method was as follows. 1) The 20 uL BoNT reaction was diluted to
500 uL in load buffer and set aside until needed. 2) 1 mL of the
elution buffer was pushed through the avidin column. 3) 2 mL of the
load buffer was pushed through the avidin column. 4) The 500 uL
sample was then pushed through the avidin column. 5) 1 mL of wash
#1 buffer was pushed through the avidin column. 6) 1 mL of wash #2
buffer was pushed through the avidin column. 7) 50 uL of elution
buffer was then pushed through the avidin column. 8) 750 uL of
elution buffer was then pushed through the avidin column and this
eluent was collected and set aside until needed. 9) 2 mL of
additional elution buffer was pushed through the avidin column. 10)
2 mL of load buffer was pushed through the avidin column. 11) 2 mL
of storage buffer was pushed through the avidin column which was
then stored at 4.degree. C. until needed again. 12) The 750 uL
fraction was lyophilized to dryness and reconstituted in 10 uL of
matrix solution. 13) The sample and matrix mixture was applied to a
MALDI plate and analyzed by MALDI-TOF MS using a 4700 Proteomics
analyzer (Applied Biosystems).
EXAMPLE 5
For the ENDOPEP-MS method, BoNTs A, B, E, and F proteolytic
activities were determined in 20-uL volumes containing 0.05 M
Hepes, pH 7.3, 25 mM DTT, 20 mM ZnCl.sub.2 (reaction buffer) 1
mg/mL bovine serum albumin (BSA) along with the target peptides, at
1 nmole each. Specific BoNT serotype complexes were added at
various concentrations, and incubated at 37.degree. C. for 2 hours
to overnight. Control tubes with no BoNT were also run at the same
time as the BoNT cleavage reactions and served as an analytical
blank. Endopeptidase reactions were multiplexed by adding all four
peptides (1-4) at 1 nmole each, to the reaction buffer described
above. BoNT-A titrated from 100 to 0.01 U/.mu.L was spiked at 1
.mu.L in reaction buffer alone and with 1 .mu.L milk, yogurt,
cheese, beef, sausage, serum, and stool.
Specific cleavage products were detected by mass spectrometry. For
all experiments, the reaction mixture, at the incubation times
indicated, was added to alpha-cyano-4-hydroxy cinnamic acid (CHCA)
at 5 mg/ml in 50% acetonitrile, 0.1% trifluoroacetic acid, and 1 mM
ammonium citrate (CHCA matrix), at a ratio of 1:5 or 1:10. This mix
was applied at 0.5 .mu.L per spot to a 192 spot MALDI plate
(Applied Biosystems, Framingham, Mass.). Mass spectra of each spot
were obtained by scanning from 650 to 4500 m/z in MS positive ion
reflectron mode on a Model 4700 MALDI-TOF-MS Proteomics Analyzer
(Applied Biosystems, Toronto, Canada). The instrument used a
nitrogen laser at 337 nm and each spectrum was an average of 2400
laser shots.
The LC-ESI/MS/MS system consisted of an API4000 triple quadrupole
mass spectrometer with a standard TurboIonSpray.RTM. interface
(Applied Biosystems, Toronto, Canada) and a Shimadzu (Kyoto, Japan)
liquid chromatograph. Luna C18 (Phenomenex, Torrance, Calif., USA)
columns (150 mm.times.1 mm I.D., 5 .mu.m particles) were used.
Solvents were A: H.sub.2O with 1% (v/v) formic acid and B: 80:20
acetonitrile:H.sub.2O plus 1% (v/v) formic acid. Peptides were
eluted with a linear gradient of 0 to 80% solvent B in 25 minutes,
at 50 .mu.L/min. A parallel column format was used, giving a cycle
time of 34 minutes. Tandem MS was performed by monitoring two
precursor to product transitions under individually optimized
conditions, typically from the most abundant [M+nH].sup.n+
precursor ion to an immonium ion. Leucine enkephalin
([M+H].sup.+556) was used as an internal standard for
quantification of BoNT product peptides.
Although the present invention has been described with reference to
specific details, it is not intended that such details should be
regarded as limitations upon the scope of the invention, except as
and to the extent that they are included in the accompanying
claims.
SEQUENCE LISTINGS
1
SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 55 <210>
SEQ ID NO 1 <211> LENGTH: 22 <212> TYPE: PRT
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic peptide chosen such that
it is cleaved by a Botulinum Neurotoxin (BoNT) <220> FEATURE:
<221> NAME/KEY: MISC_FEATURE <222> LOCATION: (1)..(22)
<223> OTHER INFORMATION: Biotin bound at each terminus of
protein <400> SEQUENCE: 1 Lys Gly Ser Asn Arg Thr Arg Ile Asp
Glu Ala Asn Gln Arg Ala Thr 1 5 10 15 Arg Met Leu Gly Gly Lys 20
<210> SEQ ID NO 2 <211> LENGTH: 22 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic peptide chosen such that
it is cleaved by a a Botulinum Neurotoxin (BoNT) <220>
FEATURE: <221> NAME/KEY: MISC_FEATURE <222> LOCATION:
(1)..(22) <223> OTHER INFORMATION: Biotin bound at each
terminus of protein <220> FEATURE: <221> NAME/KEY:
MISC_FEATURE <222> LOCATION: (18)..() OTHER INFORMATION: Xaa
can represent either Nle or Met SEQUENCE: 2 Lys Gly Ser Asn Arg Thr
Arg Ile Asp Gln Gly Asn Gln Arg Ala Thr 1 5 10 15 Arg Xaa Leu Gly
Gly Lys 20 <210> SEQ ID NO 3 <211> LENGTH: 22
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
peptide chosen such that it is cleaved by a Botulinum Neurotoxin
(BoNT) <220> FEATURE: <221> NAME/KEY: MISC_FEATURE
<222> LOCATION: (1)..(22) <223> OTHER INFORMATION:
Biotin bound at each terminus of protein <220> FEATURE:
<221> NAME/KEY: MISC_FEATURE <222> LOCATION: (8)..()
<223> OTHER INFORMATION: Ile at no. 8 includes additional 7
amu's <220> FEATURE: <221> NAME/KEY: MISC_FEATURE
<222> LOCATION: (15)..() <223> OTHER INFORMATION:
Alanine at no. 15 includes additional 7 amu's <220> FEATURE:
<221> NAME/KEY: MISC_FEATURE <222> LOCATION: (18)..()
<223> OTHER INFORMATION: Xaa can represent either Nle or Met
<400> SEQUENCE: 3 Lys Gly Ser Asn Arg Thr Arg Ile Asp Gln Gly
Asn Gln Arg Ala Thr 1 5 10 15 Arg Xaa Leu Gly Gly Lys 20
<210> SEQ ID NO 4 <211> LENGTH: 22 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic peptide chosen such that
it is cleaved by a Botulinum Neurotoxin (BoNT) <220> FEATURE:
<221> NAME/KEY: MISC_FEATURE <222> LOCATION: (1)..(22)
<223> OTHER INFORMATION: Biotin bound at each terminus of
protein <220> FEATURE: <221> NAME/KEY: MISC_FEATURE
<222> LOCATION: (18)..() <223> OTHER INFORMATION: Xaa
can represent either Nle or Met <400> SEQUENCE: 4 Lys Gly Ser
Asn Arg Thr Arg Ile Asp Glu Gly Asn Gln Arg Ala Thr 1 5 10 15 Arg
Xaa Leu Gly Gly Lys 20 <210> SEQ ID NO 5 <211> LENGTH:
22 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
peptide chosen such that it is cleaved by a Botulinum Neurotoxin
(BoNT) <220> FEATURE: <221> NAME/KEY: MISC_FEATURE
<222> LOCATION: (8)..() <223> OTHER INFORMATION: Ile at
no. 8 includes additional 7 amu's <220> FEATURE: <221>
NAME/KEY: MISC_FEATURE <222> LOCATION: (15)..() <223>
OTHER INFORMATION: Alanine at no. 15 includes additional 7 amu's
<220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222>
LOCATION: (18)..() <223> OTHER INFORMATION: Xaa can represent
either Nle or Met <400> SEQUENCE: 5 Lys Gly Ser Asn Arg Thr
Arg Ile Asp Glu Gly Asn Gln Arg Ala Thr 1 5 10 15 Arg Xaa Leu Gly
Gly Lys 20 <210> SEQ ID NO 6 <211> LENGTH: 17
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
peptide chosen such that it is cleaved by a Botulinum Neurotoxin
(BoNT) <400> SEQUENCE: 6 Ser Asn Lys Thr Arg Ile Asp Glu Ala
Asn Gln Arg Ala Thr Lys Met 1 5 10 15 Leu <210> SEQ ID NO 7
<211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic peptide chosen such that it is cleaved by a
Botulinum Neurotoxin (BoNT) <400> SEQUENCE: 7 Ser Asn Arg Thr
Arg Ile Asp Gln Gly Asn Gln Arg Ala Thr Arg Met 1 5 10 15 Leu
<210> SEQ ID NO 8 <211> LENGTH: 17 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic peptide chosen such that
it is cleaved by a Botulinum Neurotoxin (BoNT) <400>
SEQUENCE: 8 Ser Asn Arg Thr Arg Ile Asp Gln Gly Asn Gln Arg Gly Thr
Arg Met 1 5 10 15 Leu <210> SEQ ID NO 9 <211> LENGTH:
17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
peptide chosen such that it is cleaved by a Botulinum Neurotoxin
(BoNT). <400> SEQUENCE: 9 Ser Asn Arg Thr Arg Ile Asp Gln Ala
Asn Arg Gln Ala Thr Arg Met 1 5 10 15 Leu <210> SEQ ID NO 10
<211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic peptide chosen such that it is cleaved by a
Botulinum Neurotoxin (BoNT) <220> FEATURE: <221>
NAME/KEY: MISC_FEATURE <222> LOCATION: (16)..() <223>
OTHER INFORMATION: Xaa can represent either Nle or Met <400>
SEQUENCE: 10 Ser Asn Arg Thr Arg Ile Asp Gln Ala Asn Gln Arg Ala
Thr Arg Xaa 1 5 10 15 Leu <210> SEQ ID NO 11 <211>
LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic peptide chosen such that it is cleaved by a Botulinum
Neurotoxin (BoNT) <220> FEATURE: <221> NAME/KEY:
MISC_FEATURE <222> LOCATION: (16)..() <223> OTHER
INFORMATION: Xaa can represent either Nle or Met <400>
SEQUENCE: 11 Ser Asn Arg Thr Arg Ile Asp Glu Gly Asn Gln Arg Ala
Thr Arg Xaa 1 5 10 15 Leu <210> SEQ ID NO 12 <211>
LENGTH: 17 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
peptide chosen such that it is cleaved by a Botulinum Neurotoxin
(BoNT) <220> FEATURE: <221> NAME/KEY: MISC_FEATURE
<222> LOCATION: (16)..() <223> OTHER INFORMATION: Xaa
can represent either Nle or Met <400> SEQUENCE: 12 Ser Asn
Arg Thr Arg Ile Asp Gln Gly Asn Gln Arg Gly Thr Arg Xaa 1 5 10 15
Leu <210> SEQ ID NO 13 <211> LENGTH: 39 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: synthetic peptide chosen
such that it is cleaved by a Botulinum Neurotoxin (BoNT)
<220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222>
LOCATION: (1)..(39) <223> OTHER INFORMATION: Biotin bound at
each terminus of protein <400> SEQUENCE: 13 Lys Gly Leu Ser
Glu Leu Asp Asp Arg Ala Asp Ala Leu Gln Ala Gly 1 5 10 15 Ala Ser
Gln Phe Glu Thr Ser Ala Ala Lys Leu Lys Arg Lys Tyr Trp 20 25 30
Trp Lys Asn Leu Gly Gly Lys 35 <210> SEQ ID NO 14 <211>
LENGTH: 35 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic peptide chosen such that it is cleaved by a Botulinum
Neurotoxin (BoNT) <400> SEQUENCE: 14 Leu Ser Glu Leu Asp Asp
Arg Ala Asp Ala Leu Gln Ala Gly Ala Ser 1 5 10 15 Gln Phe Glu Thr
Ser Ala Ala Lys Leu Lys Arg Lys Tyr Trp Trp Lys 20 25 30 Asn Leu
Lys 35 <210> SEQ ID NO 15 <211> LENGTH: 17 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: synthetic peptide chosen
such that it is cleaved by a Botulinum Neurotoxin (BoNT)
<400> SEQUENCE: 15 Leu Ser Glu Leu Asp Asp Arg Ala Asp Ala
Leu Gln Ala Gly Ala Ser 1 5 10 15 Gln <210> SEQ ID NO 16
<211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic peptide chosen such that it is cleaved by a
Botulinum Neurotoxin (BoNT) <220> FEATURE: <221>
NAME/KEY: MISC_FEATURE <222> LOCATION: (8)..() <223>
OTHER INFORMATION: Alanine at no. 8 includes additional 7 amu's
<400> SEQUENCE: 16 Leu Ser Glu Leu Asp Asp Arg Ala Asp Ala
Leu Gln Ala Gly Ala Ser 1 5 10 15 Gln <210> SEQ ID NO 17
<211> LENGTH: 16 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic peptide chosen such that it is cleaved by a
Botulinum Neurotoxin (BoNT) <400> SEQUENCE: 17 Leu Ser Glu
Leu Asp Asp Arg Ala Asp Ala Leu Gln Ala Gly Ala Ser 1 5 10 15
<210> SEQ ID NO 18 <211> LENGTH: 16 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic peptide chosen such that
it is cleaved by a Botulinum Neurotoxin (BoNT) <220> FEATURE:
<221> NAME/KEY: MISC_FEATURE <222> LOCATION: (8)..()
<223> OTHER INFORMATION: Alanine at no. 8 includes additional
7 amu's <400> SEQUENCE: 18 Leu Ser Glu Leu Asp Asp Arg Ala
Asp Ala Leu Gln Ala Gly Ala Ser 1 5 10 15 <210> SEQ ID NO 19
<211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic peptide chosen such that it is cleaved by a
Botulinum Neurotoxin (BoNT) <400> SEQUENCE: 19 Phe Glu Thr
Ser Ala Ala Lys Leu Lys Arg Lys Tyr Trp Trp Lys Asn 1 5 10 15 Leu
Lys <210> SEQ ID NO 20 <211> LENGTH: 18 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: synthetic peptide chosen
such that it is cleaved by a Botulinum Neurotoxin (BoNT)
<220> FEATURE: <221> NAME/KEY: MISC_FEATURE <222>
LOCATION: (5)..() <223> OTHER INFORMATION: Alanine at no. 5
includes additional 7 amu's <400> SEQUENCE: 20 Phe Glu Thr
Ser Ala Ala Lys Leu Lys Arg Lys Tyr Trp Trp Lys Asn 1 5 10 15 Leu
Lys <210> SEQ ID NO 21 <211> LENGTH: 39 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: synthetic peptide chosen
such that it is cleaved by a Botulinum Neurotoxin (BoNT)
<400> SEQUENCE: 21 Ala Gln Val Asp Glu Val Val Asp Ile Met
Arg Val Asn Val Asp Lys 1 5 10 15 Val Leu Glu Arg Asp Gln Lys Leu
Ser Glu Leu Asp Asp Arg Ala Asp 20 25 30 Ala Leu Gln Ala Gly Ala
Ser 35 <210> SEQ ID NO 22 <211> LENGTH: 17 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: synthetic peptide chosen
such that it is cleaved by a Botulinum Neurotoxin (BoNT)
<400> SEQUENCE: 22 Lys Leu Ser Glu Leu Asp Asp Arg Ala Asp
Ala Leu Gln Ala Gly Ala 1 5 10 15 Ser <210> SEQ ID NO 23
<211> LENGTH: 17 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic peptide chosen such that it is cleaved by a
Botulinum Neurotoxin (BoNT) <220> FEATURE: <221>
NAME/KEY: MISC_FEATURE <222> LOCATION: (9)..() <223>
OTHER INFORMATION: Alanine at no. 9 includes additional 7 amu's
<400> SEQUENCE: 23 Lys Leu Ser Glu Leu Asp Asp Arg Ala Asp
Ala Leu Gln Ala Gly Ala 1 5 10 15 Ser <210> SEQ ID NO 24
<211> LENGTH: 22 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic peptide chosen such that it is cleaved by a
Botulinum Neurotoxin (BoNT) <400> SEQUENCE: 24 Ala Gln Val
Asp Glu Val Val Asp Ile Met Arg Val Asn Val Asp Lys 1 5 10 15 Val
Leu Glu Arg Asp Gln 20 <210> SEQ ID NO 25 <211> LENGTH:
22 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
peptide chosen such that it is cleaved by a Botulinum Neurotoxin
(BoNT) <400> SEQUENCE: 25
Ala Gln Val Asp Glu Val Val Asp Ile Met Arg Val Asn Val Asp Lys 1 5
10 15 Val Leu Glu Arg Asp Gln 20 <210> SEQ ID NO 26
<211> LENGTH: 23 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: synthetic peptide chosen such that it is cleaved by a
Botulinum Neurotoxin (BoNT) <400> SEQUENCE: 26 Ala Gln Val
Asp Glu Val Val Asp Ile Met Arg Val Asn Val Asp Lys 1 5 10 15 Val
Leu Glu Arg Asp Gln Lys 20 <210> SEQ ID NO 27 <211>
LENGTH: 23 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic peptide chosen such that it is cleaved by a Botulinum
Neurotoxin (BoNT) <220> FEATURE: <221> NAME/KEY:
MISC_FEATURE <222> LOCATION: (1)..() <223> OTHER
INFORMATION: Alanine at no. 1 includes additional 7 amu's
<400> SEQUENCE: 27 Ala Gln Val Asp Glu Val Val Asp Ile Met
Arg Val Asn Val Asp Lys 1 5 10 15 Val Leu Glu Arg Asp Gln Lys 20
<210> SEQ ID NO 28 <211> LENGTH: 31 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic peptide chosen such that
it is cleaved by a Botulinum Neurotoxin (BoNT) <400>
SEQUENCE: 28 Ile Ile Gly Asn Leu Arg His Met Ala Leu Asp Met Gly
Asn Glu Ile 1 5 10 15 Asp Thr Gln Asn Arg Gln Ile Asp Arg Ile Met
Glu Lys Ala Asp 20 25 30 <210> SEQ ID NO 29 <211>
LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic peptide chosen such that it is cleaved by a Botulinum
Neurotoxin (BoNT) <400> SEQUENCE: 29 Ile Ile Gly Asn Leu Arg
His Met Ala Leu Asp Met Gly Asn Glu Ile 1 5 10 15 Asp Thr Gln Asn
Arg Gln Ile Asp Arg 20 25 <210> SEQ ID NO 30 <211>
LENGTH: 25 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
synthetic peptide chosen such that it is cleaved by a Botulinum
Neurotoxin (BoNT) <220> FEATURE: <221> NAME/KEY:
MISC_FEATURE <222> LOCATION: (9)..() <223> OTHER
INFORMATION: Alanine at no. 9 includes additional 7 amu's
<400> SEQUENCE: 30 Ile Ile Gly Asn Leu Arg His Met Ala Leu
Asp Met Gly Asn Glu Ile 1 5 10 15 Asp Thr Gln Asn Arg Gln Ile Asp
Arg 20 25 <210> SEQ ID NO 31 <211> LENGTH: 6
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
peptide chosen such that it is cleaved by a Botulinum Neurotoxin
(BoNT) <400> SEQUENCE: 31 Ile Met Glu Lys Ala Asp 1 5
<210> SEQ ID NO 32 <211> LENGTH: 6 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic peptide chosen such that
it is cleaved by a Botulinum Neurotoxin (BoNT) <220> FEATURE:
<221> NAME/KEY: MISC_FEATURE <222> LOCATION: (5)..()
<223> OTHER INFORMATION: Alanine at no. 8 includes additional
7 amu's <400> SEQUENCE: 32 Ile Met Glu Lys Ala Asp 1 5
<210> SEQ ID NO 33 <211> LENGTH: 36 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic peptide chosen such that
it is cleaved by a Botulinum Neurotoxin (BoNT) <220> FEATURE:
<221> NAME/KEY: MISC_FEATURE <222> LOCATION: (35)..()
<223> OTHER INFORMATION: Xaa can represent either Nle or Met
<400> SEQUENCE: 33 Ile Glu Tyr Asn Val Glu His Ala Val Asp
Tyr Val Glu Arg Ala Val 1 5 10 15 Ser Asp Thr Lys Lys Ala Val Lys
Tyr Gln Ser Lys Ala Arg Arg Lys 20 25 30 Lys Ile Xaa Ile 35
<210> SEQ ID NO 34 <211> LENGTH: 36 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic peptide chosen such that
it is cleaved by a Botulinum Neurotoxin (BoNT) <220> FEATURE:
<221> NAME/KEY: MISC_FEATURE <222> LOCATION: (35)..()
<223> OTHER INFORMATION: Xaa can represent either Nle or Met
<400> SEQUENCE: 34 Ile Glu Tyr Asn Val Glu His Ala Val Asp
Tyr Val Glu Arg Ala Val 1 5 10 15 Ser Asp Thr Lys Lys Ala Val Arg
Tyr Gln Ser Lys Ala Arg Arg Lys 20 25 30 Lys Ile Xaa Ile 35
<210> SEQ ID NO 35 <211> LENGTH: 36 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic peptide chosen such that
it is cleaved by a Botulinum Neurotoxin (BoNT) <220> FEATURE:
<221> NAME/KEY: MISC_FEATURE <222> LOCATION: (35)..()
<223> OTHER INFORMATION: Xaa can represent either Nle or Met
<400> SEQUENCE: 35 Ile Glu Tyr Asn Val Glu His Ala Val Asp
Tyr Val Glu Arg Ala Val 1 5 10 15 Ser Gln Thr Lys Lys Ala Val Arg
Tyr Gln Ser Lys Ala Arg Arg Lys 20 25 30 Lys Ile Xaa Ile 35
<210> SEQ ID NO 36 <211> LENGTH: 36 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic peptide chosen such that
it is cleaved by a Botulinum Neurotoxin (BoNT) <220> FEATURE:
<221> NAME/KEY: MISC_FEATURE <222> LOCATION: (35)..()
<223> OTHER INFORMATION: Xaa can represent either Nle or Met
<400> SEQUENCE: 36 Ile Glu Tyr Asn Val Glu His Ala Val Asp
Tyr Val Glu Arg Ala Val 1 5 10 15 Ser Gln Ser Lys Lys Ala Val Arg
Tyr Gln Ser Lys Ala Arg Arg Lys 20 25 30 Lys Ile Xaa Ile 35
<210> SEQ ID NO 37 <211> LENGTH: 17 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic peptide chosen such that
it is cleaved by a Botulinum Neurotoxin (BoNT) <220> FEATURE:
<221> NAME/KEY: MISC_FEATURE <222> LOCATION: (1)..(17)
<223> OTHER INFORMATION: amide bound at one end of the
peptide <400> SEQUENCE: 37 Ser Asn Lys Thr Arg Ile Asp Glu
Ala Asn Gln Arg Ala Thr Lys Met 1 5 10 15 Leu
<210> SEQ ID NO 38 <211> LENGTH: 17 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: synthetic peptide chosen such that
it is cleaved by a Botulinum Neurotoxin (BoNT) <220> FEATURE:
<221> NAME/KEY: MISC_FEATURE <222> LOCATION: (1)..(17)
<223> OTHER INFORMATION: amide bound at one end of the
peptide <400> SEQUENCE: 38 Ser Asn Arg Thr Arg Ile Asp Glu
Ala Asn Gln Arg Ala Thr Arg Met 1 5 10 15 Leu <210> SEQ ID NO
39 <211> LENGTH: 17 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: synthetic peptide chosen such that it is cleaved
by a Botulinum Neurotoxin (BoNT) <220> FEATURE: <221>
NAME/KEY: MISC_FEATURE <222> LOCATION: (17)..() <223>
OTHER INFORMATION: lysine MAP4 structure tree (4K2KC(Beta)A) is
bound at the C-end <220> FEATURE: <221> NAME/KEY:
MISC_FEATURE <222> LOCATION: (16)..() <223> OTHER
INFORMATION: Xaa can represent either Nle or Met <400>
SEQUENCE: 39 Ser Asn Arg Thr Arg Ile Asp Gln Gly Asn Gln Arg Ala
Thr Arg Xaa 1 5 10 15 Leu <210> SEQ ID NO 40 <211>
LENGTH: 13 <212> TYPE: PRT <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Fragment resulting from cleavage of substrate 1 by a Botulinum
Neurotoxin (BoNT) <220> FEATURE: <221> NAME/KEY:
MISC_FEATURE <223> OTHER INFORMATION: Biotin bound at the N-
terminus of the protein fragment <400> SEQUENCE: 40 Lys Gly
Ser Asn Arg Thr Arg Ile Asp Glu Ala Asn Gln 1 5 10 <210> SEQ
ID NO 41 <211> LENGTH: 9 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Fragment resulting from cleavage of substrate 1
by a Botulinum Neurotoxin (BoNT) <220> FEATURE: <221>
NAME/KEY: MISC_FEATURE <223> OTHER INFORMATION: Biotin bound
at the C- terminus of the protein fragment <400> SEQUENCE: 41
Arg Ala Thr Arg Met Leu Gly Gly Lys 1 5 <210> SEQ ID NO 42
<211> LENGTH: 14 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Fragment resulting from cleavage of substrate 1 by a
Botulinum Neurotoxin (BoNT) <220> FEATURE: <221>
NAME/KEY: MISC_FEATURE <223> OTHER INFORMATION: Biotin bound
at the N- terminus of the protein fragment <400> SEQUENCE: 42
Lys Gly Ser Asn Arg Thr Arg Ile Asp Glu Ala Asn Gln Arg 1 5 10
<210> SEQ ID NO 43 <211> LENGTH: 8 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Fragment resulting from cleavage of
substrate 1 by a Botulinum Neurotoxin (BoNT) <220> FEATURE:
<221> NAME/KEY: MISC_FEATURE <223> OTHER INFORMATION:
Biotin bound at the C- terminus of the protein fragment.
<400> SEQUENCE: 43 Ala Thr Arg Met Leu Gly Gly Lys 1 5
<210> SEQ ID NO 44 <211> LENGTH: 25 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Fragment resulting from cleavage of
substrate 28 by a Botulinum Neurotoxin (BoNT) <400> SEQUENCE:
44 Ile Ile Gly Asn Leu Arg His Met Ala Leu Asp Met Gly Asn Glu Ile
1 5 10 15 Asp Thr Gln Asn Arg Gln Ile Asp Arg 20 25 <210> SEQ
ID NO 45 <211> LENGTH: 6 <212> TYPE: PRT <213>
ORGANISM: Artificial Sequence <220> FEATURE: <223>
OTHER INFORMATION: Fragment resulting from cleavage of substrate 28
by a Botulinum Neurotoxin (BoNT) <400> SEQUENCE: 45 Ile Met
Glu Lys Ala Asp 1 5 <210> SEQ ID NO 46 <211> LENGTH: 17
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Fragment
resulting from cleavage of substrate 14 by a Botulinum Neurotoxin
(BoNT) <400> SEQUENCE: 46 Leu Ser Glu Leu Asp Asp Arg Ala Asp
Ala Leu Gln Ala Gly Ala Ser 1 5 10 15 Gln <210> SEQ ID NO 47
<211> LENGTH: 18 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Fragment resulting from cleavage of substrate 14 by a
Botulinum Neurotoxin (BoNT) <400> SEQUENCE: 47 Phe Glu Thr
Ser Ala Ala Lys Leu Lys Arg Lys Tyr Trp Trp Lys Asn 1 5 10 15 Leu
Lys <210> SEQ ID NO 48 <211> LENGTH: 23 <212>
TYPE: PRT <213> ORGANISM: Artificial Sequence <220>
FEATURE: <223> OTHER INFORMATION: Fragment resulting from
cleavage of substrate 21 by a Botulinum Neurotoxin (BoNT)
<400> SEQUENCE: 48 Ala Gln Val Asp Glu Val Val Asp Ile Met
Arg Val Asn Val Asp Lys 1 5 10 15 Val Leu Glu Arg Asp Gln Lys 20
<210> SEQ ID NO 49 <211> LENGTH: 16 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Fragment resulting from cleavage of
substrate 21 by a Botulinum Neurotoxin (BoNT) <400> SEQUENCE:
49 Leu Ser Glu Leu Asp Asp Arg Ala Asp Ala Leu Gln Ala Gly Ala Ser
1 5 10 15 <210> SEQ ID NO 50 <211> LENGTH: 22
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Fragment
resulting from cleavage of substrate 21 by a Botulinum Neurotoxin
(BoNT) <400> SEQUENCE: 50 Ala Gln Val Asp Glu Val Val Asp Ile
Met Arg Val Asn Val Asp Lys 1 5 10 15 Val Leu Glu Arg Asp Gln 20
<210> SEQ ID NO 51 <211> LENGTH: 17 <212> TYPE:
PRT <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Fragment resulting from cleavage of
substrate 21 by a Botulinum Neurotoxin (BoNT)
<400> SEQUENCE: 51 Lys Leu Ser Glu Leu Asp Asp Arg Ala Asp
Ala Leu Gln Ala Gly Ala 1 5 10 15 Ser <210> SEQ ID NO 52
<211> LENGTH: 12 <212> TYPE: PRT <213> ORGANISM:
Artificial Sequence <220> FEATURE: <223> OTHER
INFORMATION: Internal Standard <220> FEATURE: <221>
NAME/KEY: MISC_FEATURE <223> OTHER INFORMATION: Biotin bound
at the C- terminus of protein fragment <220> FEATURE:
<221> NAME/KEY: MISC_FEATURE <222> LOCATION: (12)..()
<223> OTHER INFORMATION: Biotin bound at no. 12 of protein
fragment <400> SEQUENCE: 52 Leu Arg Thr Ala Gln Ala Asp Ile
Thr Asn Ser Lys 1 5 10 <210> SEQ ID NO 53 <211> LENGTH:
17 <212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: synthetic
peptide chosen such that it is cleaved by a Botulinum Neurotoxin
(BoNT) <220> FEATURE: <221> NAME/KEY: MISC_FEATURE
<222> LOCATION: (16)..() <223> OTHER INFORMATION: X =
Norleucine <220> FEATURE: <221> NAME/KEY: misc_feature
<222> LOCATION: (16)..(16) <223> OTHER INFORMATION: Xaa
can be any naturally occurring amino acid <400> SEQUENCE: 53
Ser Asn Arg Thr Arg Ile Asp Gln Gly Asn Gln Arg Ala Thr Arg Xaa 1 5
10 15 Leu <210> SEQ ID NO 54 <211> LENGTH: 11
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Fragment
resulting from cleavage of substrate 40 by a Botulinum Neurotoxin
(BoNT) <400> SEQUENCE: 54 Ser Asn Arg Thr Arg Ile Asp Gln Gly
Asn Gln 1 5 10 <210> SEQ ID NO 55 <211> LENGTH: 6
<212> TYPE: PRT <213> ORGANISM: Artificial Sequence
<220> FEATURE: <223> OTHER INFORMATION: Fragment
resulting from cleavage of substrate 40 by a Botulinum Neurotoxin
(BoNT) <220> FEATURE: <221> NAME/KEY: MISC_FEATURE
<222> LOCATION: (5)..() <223> OTHER INFORMATION:
X=Norleucine <220> FEATURE: <221> NAME/KEY:
misc_feature <222> LOCATION: (5)..(5) <223> OTHER
INFORMATION: Xaa can be any naturally occurring amino acid
<400> SEQUENCE: 55 Arg Ala Thr Arg Xaa Leu 1 5
* * * * *